Seelos Therapeutics Inc (SEEL)

[eicoman]

more AF inaccurate statements:

he stated early in the article that Vitaros was targeting men who can't or won't take PDE5's, then he says Vitaros will have to compete with generic PDE5's in the EU, a contradiction of his own words, a real idiot,

he also suggests that we don't know if the China studies will be sufficient for an NDA in the US, when APRI has clearly stated they have positive feeback on establishing new PH3 trials for Femprox in the USA, so he really is ill informed and his comment on ABT is most likely just based on rumor.


Abbott is trying to create a shelf-stable formulation of Vitaros that won't require refrigeration. The latest launch date is 2014, or more than two years later than expected.

Apricus has partners lined up to launch Vitaros in Germany and Italy, but there, the drug will have significant marketing challenge from generic versions of Viagra expected soon.